Cyclacel Pharmaceuticals (CYCC) Institutional Ownership $8.20 -4.13 (-33.50%) Closing price 04:00 PM EasternExtended Trading$8.12 -0.08 (-1.04%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cyclacel Pharmaceuticals (NASDAQ:CYCC)CurrentInstitutional OwnershipPercentage23.58%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$98.27MNumber ofInstitutional Sellers(last 12 months)0 Get CYCC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclacel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYCC Institutional Buying and Selling by Quarter Cyclacel Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/15/2025Armistice Capital LLC1,269,485$354K0.0%+118.7%0.612% 8/15/2024Armistice Capital LLC134,000$217K0.0%N/A9.178% 5/10/2024Acadian Asset Management LLC14,285$29K0.0%-41.0%1.084% 11/1/2022Kestra Advisory Services LLC23,000$34K0.0%N/A0.183% 10/25/2022Raymond James Financial Services Advisors Inc.20,806$30K0.0%-32.5%0.166% 10/18/2022McIlrath & Eck LLC26,342$38K0.0%N/A0.210% 8/15/2022Sio Capital Management LLC454,355$491K0.2%+7.5%4.546% 2/10/2022Acadian Asset Management LLC23,242$89K0.0%N/A0.233% 11/16/2021Two Sigma Advisers LP121,500$640K0.0%+929.7%1.316% 11/15/2021Pura Vida Investments LLC105,141$554K0.0%-33.2%1.139% Get the Latest News and Ratings for CYCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/2021Tri Locum Partners LP522,943$2.76M1.1%+66.9%5.663% 11/12/2021Affinity Asset Advisors LLC400,000$2.11M0.5%+5.3%4.332% 11/2/2021Raymond James Financial Services Advisors Inc.10,006$53K0.0%-83.3%0.108% 10/15/2021NEXT Financial Group Inc14,752$77K0.0%+70.0%0.160% 8/18/2021Ikarian Capital LLC100,000$593K0.0%-66.7%1.083% 8/17/2021Boothbay Fund Management LLC10,545$62K0.0%-66.7%0.114% 8/17/2021Citadel Advisors LLC250,797$1.49M0.0%-14.7%2.716% 8/16/2021Tri Locum Partners LP313,331$1.86M0.6%+6.8%3.393% 8/16/2021Schonfeld Strategic Advisors LLC102,525$607K0.0%-25.0%1.110% 8/16/2021Maven Securities LTD234,500$1.43M0.1%-6.2%2.540% 8/13/2021Northern Trust Corp14,957$89K0.0%N/A0.162% 8/13/2021Geode Capital Management LLC50,860$301K0.0%+143.3%0.551% 8/13/2021Vanguard Group Inc.327,658$1.94M0.0%+9.2%3.548% 7/31/2021NEXT Financial Group Inc8,680$51K0.0%N/A0.094% 5/19/2021Virtu Financial LLC13,108$93K0.0%+27.3%0.142% 5/19/2021Squarepoint Ops LLC23,836$169K0.0%N/A0.258% 5/18/2021Point72 Asset Management L.P.230,000$1.64M0.0%N/A2.491% 5/18/2021Verition Fund Management LLC116,674$830K0.0%N/A1.264% 5/18/2021Morgan Stanley100,000$711K0.0%-13.0%1.083% 5/18/2021Citadel Advisors LLC293,867$2.09M0.0%N/A3.182% 5/17/2021Schonfeld Strategic Advisors LLC136,725$972K0.0%N/A1.481% 5/12/2021Geode Capital Management LLC20,904$148K0.0%N/A0.226% (Data available from 1/1/2016 forward) CYCC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYCC shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclacel Pharmaceuticals shares: Armistice Capital LLC ($354K), Acadian Asset Management LLC ($29K).Learn more on Cyclacel Pharmaceuticals' institutional investors. What percentage of Cyclacel Pharmaceuticals' stock is owned by institutional investors? 23.58% of Cyclacel Pharmaceuticals' stock is owned by institutional investors. Learn more on CYCC's institutional investor holdings. Which institutional investors have been buying Cyclacel Pharmaceuticals' stock? The following institutional investors have purchased Cyclacel Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($823.02K). How much institutional buying is happening at Cyclacel Pharmaceuticals? Institutional investors have bought a total of 823,024 shares in the last 24 months. This purchase volume represents approximately $98.27M in transactions. Related Companies NanoViricides Institutional Ownership BioAtla Institutional Ownership Chemomab Therapeutics Institutional Ownership VYNE Therapeutics Institutional Ownership Aytu BioPharma Institutional Ownership Dare Bioscience Institutional Ownership Relmada Therapeutics Institutional Ownership Sol-Gel Technologies Institutional Ownership DURECT Institutional Ownership MIRA Pharmaceuticals Institutional Ownership This page (NASDAQ:CYCC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts